Search Tag: Radiopharmaceutical
2022 04 Oct
Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugs Viewpoint Molecular Targeting, Inc, a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents announced the...Read more
2017 04 Jun
Scientists from Tomsk Polytechnic University, Tomsk Research Institute of Oncology and the Institute of Biorganic Chemistry of the Russian Academy of Sciences have developed a radiopharmaceutical for advanced identification of cancer. Labelled as the technetium-99 isotope, the medication is ready for pre-clinical phase trial. The radiopharmaceutical...Read more